


## HDAC-IN-48

Cat. No.:	HY-151872
CAS No.:	3031411-05-6
Molecular Formula:	C <sub>13</sub> H <sub>17</sub> N <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	295.36
Target:	HDAC; Ferroptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	HDAC-IN-48 is a potent HDAC inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI <sub>50</sub> ~20 nM). HDAC-IN-48 consists ofarmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits HDAC proteins <sup>[1]</sup> . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.																
In Vitro	<p>HDAC-IN-48 (0-40 μM; 3 d) has superior antiproliferative activity on cancer cells (NCI-H522 and HCT-116) vs the normal cells (WI38 and RPE) with IC<sub>50</sub>s of 0.5 μM (NCI-H522), 0.61 μM (HCT-116), 8.37 μM (WI38, normal human lung fibroblasts), and 6.13 μM (RPE, retinal pigment epithelial cells), respectively<sup>[1]</sup>.</p> <p>HDAC-IN-48 (2.5 μM; 24 h) suppresses cell viability by inducing ferroptosis and HDAC inhibition<sup>[1]</sup>.</p> <p>HDAC-IN-48 (10 μM; 6 h) decreases the lipid peroxide level compared with SAHA<sup>[1]</sup>.</p> <p>HDAC-IN (0.58 μM, 1.16 μM, and 2.32 μM; 3 d) has no neurotoxic effects and (2.5, 5, and 10 μM; 3 d) leads to hyper acetylation of histones and tubulin<sup>[1]</sup>.</p> <p>Nondifferentiated PC-12 cells have stem-like properties, but when differentiated by a nerve growth factor, they demonstrate neuronal behavior. HDAC-IN-48 (0.58 μM, 1.16 μM, and 2.32 μM; 24 h) behaves as the HDAC control effect, shows few ferroptosis induction on both differentiated and undifferentiated PC-12 cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td><td>NCI-H522 cells</td></tr> <tr> <td>Concentration:</td><td>2.5, 5, and 10 μM</td></tr> <tr> <td>Incubation Time:</td><td>72 hours; at the corresponding concentrations in the presence of Liproxstatin-1 (0.25 μM)</td></tr> <tr> <td>Result:</td><td>Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).</td></tr> </table> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td><td>NCI-H522, WI38, HCT-116, and RPE</td></tr> <tr> <td>Concentration:</td><td>0-40 μM</td></tr> <tr> <td>Incubation Time:</td><td>72 hours</td></tr> <tr> <td>Result:</td><td>Showed selectivity among normal cells over cancer cells.</td></tr> </table>	Cell Line:	NCI-H522 cells	Concentration:	2.5, 5, and 10 μM	Incubation Time:	72 hours; at the corresponding concentrations in the presence of Liproxstatin-1 (0.25 μM)	Result:	Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).	Cell Line:	NCI-H522, WI38, HCT-116, and RPE	Concentration:	0-40 μM	Incubation Time:	72 hours	Result:	Showed selectivity among normal cells over cancer cells.
Cell Line:	NCI-H522 cells																
Concentration:	2.5, 5, and 10 μM																
Incubation Time:	72 hours; at the corresponding concentrations in the presence of Liproxstatin-1 (0.25 μM)																
Result:	Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).																
Cell Line:	NCI-H522, WI38, HCT-116, and RPE																
Concentration:	0-40 μM																
Incubation Time:	72 hours																
Result:	Showed selectivity among normal cells over cancer cells.																

	Inhibited cell survival with IC50s of 0.5 $\mu$ M, 8.37 $\mu$ M, 0.61 $\mu$ M, and 6.13 $\mu$ M.
--	--

#### Apoptosis Analysis<sup>[1]</sup>

Cell Line:	NCI-H522 cells
------------	----------------

Concentration:	5 $\mu$ M
----------------	-----------

Incubation Time:	24 hours, 48 hours, and 72 hours
------------------	----------------------------------

Result:	Induced cell ferroptosis.
---------	---------------------------

## REFERENCES

[1]. Karaj E, et al. First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids. J Med Chem. 2022 Nov 10;65(21):14764-14791.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA